Free Trial
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

Galera Therapeutics logo
$0.02 0.00 (-7.41%)
As of 08/29/2025 03:26 PM Eastern

About Galera Therapeutics Stock (NASDAQ:GRTX)

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.08
Volume
364,798 shs
Average Volume
90,052 shs
Market Capitalization
$1.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GRTX Stock News Headlines

GRTX Galera Therapeutics, Inc. - Seeking Alpha
"I'm risking my reputation on this"
A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That's why we've rushed to update our book "Crypto Revolution" – to show you exactly how to position yourself for this historic opportunity.tc pixel
Galera Therapeutics extends agreement deadline
See More Headlines

GRTX Stock Analysis - Frequently Asked Questions

Galera Therapeutics' stock was trading at $0.0458 at the beginning of 2025. Since then, GRTX stock has decreased by 56.3% and is now trading at $0.02.

Galera Therapeutics, Inc. (NASDAQ:GRTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by $0.15.

Galera Therapeutics (GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager.

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Galera Therapeutics investors own include Energy Transfer (ET), Plug Power (PLUG), NGL Energy Partners (NGL), Universal Display (OLED), Nextera Energy Partners (NEP), Verastem (VSTM) and Alerian MLP ETF (AMLP).

Company Calendar

Last Earnings
11/10/2021
Today
9/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GRTX
CIK
1563577
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$59.08 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-99.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.74
Quick Ratio
9.74

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($2.41) per share
Price / Book
-0.01

Miscellaneous

Outstanding Shares
75,462,000
Free Float
47,375,000
Market Cap
$1.51 million
Optionable
Optionable
Beta
1.91
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:GRTX) was last updated on 9/1/2025 by MarketBeat.com Staff
From Our Partners